India is soon set to begin human trials on its first home-grown Covid vaccine based on Messenger RNA (mRNA) technology.
Pune-based Gennova Biopharmaceuticals is making India's first mRNA vaccine known as HGC019, in collaboration with US-based HDT Bio Corp.
In August, the Drug Controller General of India had approved the Phase 2 and 3 clinical trials.
"The Vaccine Subject Expert Committee (SEC) reviewed the data, and found HGCO19 to be safe, tolerable, and immunogenic in the participants of the study," the company had said in a statement.
The company will start testing the vaccine on humans for efficacy and immunogenicity from next month. The mRNA vaccine is also reportedly effective against the newA Omicron variant.
The mRNA vaccines carry the molecular information to make the protein in the host using the synthetic RNA of the virus. The host body produces the viral protein that is recognised by the immune system, thereby enabling the body to fight against the disease.